Phase 2 study of PTM-101
Latest Information Update: 23 Aug 2022
At a glance
- Drugs Paclitaxel (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 23 Aug 2022 New trial record
- 22 Aug 2022 According to a PanTher Therapeutics media release, the company received a $14.2 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT) that will be used to expand clinical development through Phase 2 study.